OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of "Hold" by Brokerages

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) has received a consensus rating of "Hold" from the five ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $1.55.

OPK has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating on shares of OPKO Health in a research note on Wednesday, July 29th. Wall Street Zen upgraded OPKO Health from a "sell" rating to a "hold" rating in a research note on Saturday, June 6th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of OPKO Health in a research report on Thursday, August 13th.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.64 on Tuesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.35 and a quick ratio of 2.93. The firm has a market cap of $1.22 billion, a PE ratio of -18.22 and a beta of 1.50. The firm has a 50 day simple moving average of $1.40 and a 200-day simple moving average of $1.30. OPKO Health has a 1-year low of $0.98 and a 1-year high of $1.73.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.07. The firm had revenue of $163.58 million for the quarter, compared to analyst estimates of $131.23 million. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. OPKO Health's revenue was up 4.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.19) earnings per share. On average, equities analysts expect that OPKO Health will post -0.23 EPS for the current year.

Institutional Investors Weigh In On OPKO Health

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in OPKO Health during the second quarter worth approximately $55,468,000. Goldman Sachs Group Inc. boosted its holdings in shares of OPKO Health by 150.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company's stock valued at $7,544,000 after purchasing an additional 3,600,378 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in shares of OPKO Health during the 2nd quarter valued at $3,165,000. Millennium Management LLC grew its stake in shares of OPKO Health by 39.2% during the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company's stock valued at $10,602,000 after buying an additional 1,798,385 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of OPKO Health during the 2nd quarter worth $1,995,000. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc NASDAQ: OPK is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.